PAR-17-237: Centers for AIDS Research (P30)
Internal Deadline: May 26, 2018, 5pm PDT
LOI: 30 days prior to the application due date
External Deadline: August 1, 2018, 5pm PDT
Award Information: Type: Grant
Estimated Number of Awards: The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.
Anticipated Amount: A base of up to $3M total costs per center per year will be awarded. The total amount awarded will depend on the applicant institutions’ NIH HIV/AIDS-funded research base.
Submission Process: PIs must submit their application as a Limited Submission through the Office of Research Application Portal: https://app.wizehive.com/webform/USCgrants
Materials to submit:
- Single Page Proposal Summary (0.5” margins; single-spaced; font type: Arial, Helvetica, or Georgia typeface; font size: 11 pt). Page limit includes references and illustrations. Pages that exceed the 1-page limit will be excluded from review.
- CV – (5 pages maximum)
Link to Award: https://grants.nih.gov/grants/guide/pa-files/PAR-17-237.html
Who May Serve as PI: Standard NIH requirements.
NIH AIDS Funded Research Base (FRB)
Institutions/Organizations with a HIV/AIDS FRB of $10M annually (minimum) are eligible for a CFAR award. Amounts in excess of $10M will result in a larger base award. The NIH HIV/AIDS FRB is defined as the amount of Total Cost funding from NIH for one fiscal year (October 1 to September 30) preceding the calendar year of application submission. CFAR applicants must maintain the required minimum FRB during the year of submission in order to be funded at the requested amount, and applicants eligible for larger base funding must maintain that minimum level in order to qualify for subsequent funding at that level. See the RFA for more specific details.
The FRB includes NIH peer-reviewed HIV/AIDS research grants, program projects, and cooperative agreements utilizing the following mechanisms only: DP1, DP2, P01, P50 (only the NIGMS Specialized Centers for HIV/AIDS-Related Structural Biology), R00, R01, R03, R15, R21, R24, R33, R34, R35, R37, R56, R61, SC1, SC2, SC3, U01, U10, U19, U24, UH2, UH3, UG3, and K series awards. On a case-by-case basis, the following mechanisms will be considered based on whether or not the award involves primarily research activity: KL1, KL2, N01, PM1, U54, UG1, UM1, UM2 and RC series grants. Excluded from the NIH AIDS FRB are all funds from any source other than NIH. Additionally, only the amount budgeted directly to an applicant institution(s) will be included for grants over $5M in the FRB.
Multi-institutional CFAR applications may combine the NIH HIV/AIDS-funded research of all the investigators at the institutions participating in the proposed CFAR to meet the NIH AIDS-FRB eligibility. A CFAR applicant cannot use the FRB of an institution that is already part of another CFAR or D-CFAR. CFARs that use a distant institution for a core facility may not use the Funded Research of that institution if they are not including all of the NIH AIDS investigators at that institution as part of the CFAR. The NIH AIDS FRB is compiled from the NIH Office of AIDS Research and can be requested by the applicant institution to determine eligibility.
No institution may have more than one CFAR or D-CFAR award concurrently. An institution that is part of a multi-institutional CFAR or D-CFAR application or award may not be listed as a multi-institutional participant in a CFAR application. Independent campuses that are part of a large multiple city university are considered to be separate institutions, and each may submit one application.
In some cases two or more institutions that can demonstrate a credible plan for collaborative research networks using CFAR cores may wish to submit an application for a single CFAR award. A multi-institutional CFAR application must designate a lead institution that will receive the award, should demonstrate sharing in leadership positions, and provide details of agreements regarding coordination and support of cores and activities at other participating institutions.
With appropriate justification, CFAR awards may support a core at an institution that is not part of the CFAR, including a primate facility or a foreign institution that provides a unique resource such as a clinical and/or laboratory site.
The Centers for AIDS Research (CFAR) program supports research and administrative infrastructure and translational HIV/AIDS research activities at institutions that receive significant HIV/AIDS funding from NIH Institutes or Centers. CFARs are designed to foster synergy and improve coordination of research, support emerging research opportunities, and promote efficiencies through resources shared by multiple independent laboratories. CFARs are intended to promote NIH HIV/AIDS research efforts at CFAR institution(s). The proposed CFAR priorities should align with the NIH HIV/AIDS priority topics of research for support using AIDS-designated funds (NOT-OD-15-137).
The Centers for AIDS Research program was established in 1988 and renewed through 2017. The mission of the CFAR program and mechanisms for achieving the mission were developed by the CFAR Directors (https://www.niaid.nih.gov/research/centers-aids-research). The CFAR program accomplishes this mission by:
- Providing scientific leadership and institutional infrastructure dedicated to HIV/AIDS research
- Stimulating scientific collaboration in interdisciplinary and translational research
- Strengthening capacity for HIV/AIDS research in resource-limited settings
- Fostering scientific communication
- Sponsoring opportunities in support of early career investigators and investigators new to the field of HIV/AIDS
- Promoting knowledge of CFAR research findings and the importance of HIV/AIDS research through community outreach
- Promoting and supporting innovative NIH HIV/AIDS research
- Establishing collaborative research between and among CFARs, and supporting HIV/AIDS research networks
- Facilitating technology transfer and development through promotion of scientific interactions between CFARs
- Supporting research on prevention and treatment of HIV infection in marginalized and hard-to-reach populations, especially inner city, rural poor, and disadvantaged minorities or severely affected populations in low and/or middle income countries (LMIC) countries.
Expected characteristics include:
- Added value.
- Developmental Core awards resulting in collaborations, publications, or successful major research grants, especially among early career investigators and investigators new to the field of HIV/AIDS
- Evidence of an increase in multidisciplinary research and publications
- Evidence of CFAR enhancement and support of existing programs at the award institution
- Research activities focused on prevention, treatment and implementation science questions in marginalized and hard-to-reach populations
- Commitment from the institution for support of CFAR activities
- Mentoring early career investigators in the HIV/AIDS research field and facilitating the transition to independence
- Promoting and supporting new collaborations designed to move the HIV/AIDS field forward through CFAR-sponsored meetings and activities
- Increase in percentage of NIH funded HIV researchers supported by the CFAR
- Development and implementation of a cost recovery system for science cores
- Scientific and fiscal flexibility.
- NIH-funded HIV/AIDS investigators at the applicant institutions.
- Collaborations with community groups, organizations, and other institutions.
The overall structure of the CFAR is designed to support the HIV/AIDS researchers at the applicant institution in the conduct of their research projects, interact with a variety of organizations to promote collaborations that serve the applicant organization, and create linkages for promoting additional HIV/AIDS research in key areas identified by the community.
Cores and Core services provide support of specific functions that facilitate HIV/AIDS research at the CFAR institution, therefore, Cores must specifically target HIV/AIDS research. (e.g. Administrative, Developmental, Basic Science, Clinical Science, etc.)
High Priority topics of research for support using AIDS-designated funds
- Reducing Incidence of HIV/AIDS including: developing and testing promising vaccines, developing and testing microbicide and pre-exposure prophylaxis candidates and methods of delivery, especially those that mitigate adherence issues; and developing, testing, and implementing strategies to improve HIV testing and entry into prevention services.
- Next generation of HIV therapies with better safety and ease of use including: developing and testing HIV treatments that are less toxic, longer acting, have fewer side effects and complications, and easier to take and adhere to than current regimens. Additionally, implementation research to ensure initiation of treatment as soon as diagnosis has been made, retention and engagement in these services, and achievement and maintenance of optimal prevention and treatment responses.
- Research toward a cure including: developing novel approaches and strategies to identify and eliminate viral reservoirs that could lead toward a cure or lifelong remission of HIV infection, including studies of viral persistence, latency, reactivation, and eradication.
- HIV-associated comorbidities, coinfections, and complications including: addressing the impact of HIV-associated comorbidities, including tuberculosis, malignancies; cardiovascular, neurological, and metabolic complications; and premature aging associated with long-term HIV disease and antiretroviral therapy.
- Cross cutting areas: Basic research, health disparities, and training including:
- Basic Research: understanding the basic biology of HIV transmission and pathogenesis; immune dysfunction and chronic inflammation; host microbiome and genetic determinants; and other fundamental issues that underpin the development of high priority HIV prevention, cure, co-morbidities, and treatment strategies.
- Research to Reduce Health Disparities in the incidence of new HIV infections or in treatment outcomes of those living with HIV/AIDS.
- Research Training of the workforce required to conduct High Priority HIV/AIDS or HIV/AIDS-related research.
Medium Priority topics of research for support using AIDS-designated funds include projects that demonstrate HIV/AIDS is a meaningful component of the project and/or knowledge about HIV will be enhanced by the project, as evidenced in the specific aims.
Several examples of research that could be considered as Medium Priority include:
- The project examines a fundamental scientific question (or questions) that has a clear or potential link to HIV/AIDS;
- The project includes people (or biological specimens from people) who are living with HIV, are HIV exposed, and/or are at elevated risk for HIV infection as part of a broader sample or as a comparative cohort;
- The project addresses health and social issues that are clearly linked with HIV (transmission/acquisition, pathogenesis, morbidity and mortality, stigma) and examines them in the context of HIV (i.e., in populations or settings with high HIV prevalence or incidence), such as other infectious pathogens and diseases, non-infectious pathogens and diseases, substance use/addiction, and mental health disorders;
- The project meaningfully includes HIV/AIDS (or SIV) outcomes/endpoints; or
- The results of the project will advance HIV treatment or prevention and/or provide tools/techniques and/or capacity beneficial to HIV research (including training and infrastructure development).
Low Priority topics of research will not be supported with AIDS-designated funds; however, highly meritorious projects could be eligible for support with non-AIDS funds by an NIH Institute or Center. Several examples of research that will be considered Low Priority include:
- Research on natural history and epidemiology that is entirely focused on a co-morbidity and does not have any focus on or inclusion of HIV (e.g., malaria, TB, and drug abuse);
- Basic virology research on pathogens that are co-infecting, but not in the context of HIV infection; and basic immunology studies of general relevance, but not specific to HIV including – basic virology and neurobiology research of co-infecting pathogens not in the context of HIV infection (e.g., Herpesviruses, HPV, TB, Malaria, hepatitis C and B, syphilis, Cryptococcus, flaviviruses, JC virus, etc.); basic cancer-related immunology studies not in the context of HIV infection; or studies on co-morbidities of general relevance, but not in the context of HIV (e.g., diabetes, lipid defects, endocrinology);
- Data analysis and systems tools that are not HIV-related, e.g., genomics studies of little or no relevance to HIV; or
- Studies of behaviors (e.g., sexual activities, drug use activities) or social conditions that have multiple negative outcomes where HIV/AIDS is only one of many outcomes being studied without a focus on how HIV/AIDS is unique in that context.
Visit our Institutionally Limited Submission webpage for updates and other announcements.